Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 860,088,000
  • Shares Outstanding, K 950,405
  • Annual Sales, $ 34,124 M
  • Annual Income, $ 5,240 M
  • 60-Month Beta 0.42
  • Price/Sales 25.24
  • Price/Cash Flow 121.10
  • Price/Book 64.37
Trade LLY with:

Options Overview Details

View History
  • Implied Volatility 26.49% ( -1.79%)
  • Historical Volatility 36.69%
  • IV Percentile 26%
  • IV Rank 13.94%
  • IV High 55.08% on 08/05/24
  • IV Low 21.86% on 09/20/23
  • Put/Call Vol Ratio 0.71
  • Today's Volume 38,637
  • Volume Avg (30-Day) 42,084
  • Put/Call OI Ratio 1.01
  • Today's Open Interest 315,629
  • Open Int (30-Day) 305,482

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 4.53
  • Number of Estimates 9
  • High Estimate 5.01
  • Low Estimate 4.16
  • Prior Year 0.10
  • Growth Rate Est. (year over year) +4,430.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
893.00 +2.47%
on 09/06/24
972.53 -5.91%
on 08/22/24
-6.77 (-0.73%)
since 08/19/24
3-Month
747.55 +22.41%
on 08/05/24
972.53 -5.91%
on 08/22/24
+23.58 (+2.65%)
since 06/18/24
52-Week
516.57 +77.14%
on 10/03/23
972.53 -5.91%
on 08/22/24
+340.08 (+59.15%)
since 09/19/23

Most Recent Stories

More News
Why Tandem Diabetes Care Stock Thrashed the Market Today

At a stroke, it's got a product authorized for a specific use in 27 countries.

TNDM : 44.45 (+4.24%)
LLY : 915.04 (+1.11%)
Sanofi Stock Up Almost 23% in 3 Months: Buy, Sell or Hold?

Sanofi’s SNY stock has gained 22.7% in the past three months compared with an increase of 2.9% for the industry. The stock has also outperformed the sector and the S&P 500 index as seen in the chart...

SNY : 58.26 (+1.37%)
AZN : 78.90 (+0.41%)
NVO : 134.88 (+2.14%)
LLY : 915.04 (+1.11%)
Pfizer Stock Rises 7.3% in 3 Months: Should You Invest Now?

Pfizer PFE stock has risen 7.3% in the past three months compared with an increase of 2.9% for the industry. The stock has also outperformed the sector as well as the S&P 500, as seen in the chart below.PFE...

PFE : 29.66 (-0.30%)
NVO : 134.88 (+2.14%)
LLY : 915.04 (+1.11%)
1 Unstoppable Stock That Could Join the $1 Trillion Club in 2025

Eli Lilly stock may look expensive, but that may not be the case in a few years as the business grows at a rapid pace.

BRK.A : 687,840.00 (+0.14%)
BRK.B : 459.71 (+0.68%)
LLY : 915.04 (+1.11%)
Prediction: This Will be Eli Lilly's Next Big Move.

Lilly could take a step that's positive for the stock and investors over the long term.

NVDA : 117.87 (+3.97%)
AVGO : 167.42 (+3.56%)
LLY : 915.04 (+1.11%)
Why ResMed Stock Tumbled by 5% Today

A looming threat from a very powerful rival could significantly dampen a key business for the company.

LLY : 915.04 (+1.11%)
RMD.AX : 35.490 (+0.45%)
RMD : 242.98 (+2.08%)
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise

Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC), patritumab deruxtecan, for treating EGFR-mutated non-small cell lung cancer...

AZN : 78.90 (+0.41%)
PFE : 29.66 (-0.30%)
MRK : 117.23 (-1.19%)
LLY : 915.04 (+1.11%)
Tap the Weight-Loss Drug Market With These ETFs

The weight-loss drug market is heating up with the introduction of GLP-1 pills. Novo Nordisk’s NVO Wegovy and Eli Lilly’s LLY Zepbound have been dominating this market and several other companies are...

RHHBY : 39.4600 (-0.38%)
NVO : 134.88 (+2.14%)
LLY : 915.04 (+1.11%)
HRTS : 35.34 (+1.93%)
THNR : 27.67 (+1.04%)
OZEM : 28.67 (+1.85%)
Novartis Wins FDA Approval of Kisqali for Early Breast Cancer

Novartis NVS announced that the FDA has approved breast cancer drug Kisqali (ribociclib) for a broader population.The regulatory body approved Kisqali in combination with an aromatase inhibitor (AI) for...

NVS : 115.98 (+0.01%)
PFE : 29.66 (-0.30%)
LLY : 915.04 (+1.11%)
This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments

Terns has a modest market cap of less than $800 million, and its possible upside could be massive.

LLY : 915.04 (+1.11%)
GS : 503.83 (+3.97%)
TERN : 10.04 (-1.67%)
VKTX : 68.16 (+5.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 932.90
2nd Resistance Point 924.85
1st Resistance Point 919.95
Last Price 915.04
1st Support Level 907.00
2nd Support Level 898.95
3rd Support Level 894.05

See More

52-Week High 972.53
Last Price 915.04
Fibonacci 61.8% 798.35
Fibonacci 50% 744.55
Fibonacci 38.2% 690.75
52-Week Low 516.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar